Hepatitis B vaccination in dialysis centres: advantages and limits

Area of Science:

• Immunology
• Vaccinology
• Nephrology

Background:

• Hemodialysis patients exhibit impaired immune responses.
• Hepatitis B virus (HBV) infection poses a significant risk to hemodialysis patients.
• Current HBV vaccines show variable efficacy in this population.

Purpose of the Study:

• To review the efficacy of different HBV vaccines in hemodialysis patients.
• To identify host-related and immunization-related factors contributing to low vaccine response.
• To explore strategies for enhancing HBV vaccine performance in hemodialysis patients.

Main Methods:

• Literature review of studies on HBV immunization in hemodialysis patients.
• Analysis of host factors (e.g., age, comorbidities) and vaccine factors (e.g., type, schedule).
• Evaluation of immunopotentiating procedures.

Main Results:

• Aluminum-adsorbed, subunit plasma-derived, and yeast-derived HBV vaccines have been used.
• Low seroconversion rates are frequently observed.
• Factors such as patient age, duration of dialysis, and immunosuppression impact response.

Conclusions:

• Optimizing HBV vaccine dosage and administration schedules is crucial.
• Immunopotentiating agents may improve vaccine response.
• Further research is needed to enhance HBV vaccine efficacy in hemodialysis patients.